Results 91 to 100 of about 7,732 (197)

Isolation of Pure Stable Human Treg Cells Based on Expression of GPA33

European Journal of Immunology, Volume 56, Issue 2, February 2026.
GPA33 identifies stable human regulatory T cells suitable for therapeutic use. GPA33+ Treg subsets expand efficiently, maintain high FOXP3+Helios+ expression, and lack production of IL‐2, IFNγ, and IL‐17A. GPA33, alone or combined with TIGIT, also enables robust post‐expansion isolation of pure, stable Treg cells for adoptive cell therapy.
Florencia Morgana, Edith Slot, Derk Amsen   +2 more
wiley   +1 more source

Absence of CD155 aggravates acute graft-versus-host disease [PDF]

Proceedings of the National Academy of Sciences, 2011
In a recent paper, Nabekura et al. (1) provided compelling evidence that abrogating DNAM-1 (DNAX accessory molecule-1; CD226) activity resulted in milder development of graft-versus-host disease (GVHD). This is expected, because the role of CD226 as an important costimulatory receptor during T-cell activation is well-documented (2, 3).
Sebastian Seth, Inga Ravens, Chun-Wei Lee, Silke Glage, Andre Bleich, Reinhold Förster, Günter Bernhardt, Christian Koenecke   +7 more
openaire   +1 more source

Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
This figure emphasizes current understanding of the regulatory networks, approach of diagnose, available preclinical models and clinical management of bone metastasis. to guide future therapeutic development. A deep understanding of these aspects enables the prevention of bone metastasis and the implementation of effective therapeutic strategies ...
Jingyuan Wen, Binghua Li, Shengjia Wang, Yongzhong Yao, Zhao Huang, Decai Yu   +5 more
wiley   +1 more source

Overexpression of CD155 relates to metastasis and invasion in osteosarcoma

Oncology Letters, 2018
The rapid development of metastatic lesions remains the leading cause of mortality for patients with osteosarcoma. CD155 serves a key role in cancer cell migration, invasion and metastasis. However, the function and mechanism of CD155 has not been explored in osteosarcoma metastasis.
Baobiao, Zhuo, Yuan, Li, Feng, Gu, Zhengwei, Li, Qingzeng, Sun, Yingchun, Shi, Yang, Shen, Fengfei, Zhang, Rong, Wang, Xiaodong, Wang   +9 more
openaire   +3 more sources

Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers [PDF]

, 2012
Technological advances now allow us to rapidly produce CARs and other antibody-derived therapeutics targeting cell surface receptors. To maximize the potential of these new technologies, relevant extracellular targets must be identified.
Crystal L. Mackall, James J. Yang, Javed Khan, Jun S. Wei, Rimas J. Orentas, Xinyu Wen   +5 more
core   +2 more sources

The Immunogenicity of Human Senescent Cells Is Dependent on the Senescence Inducer and Cell Type

Aging Cell, Volume 25, Issue 2, February 2026.
Using multiple cell types and autologous immune cells, the authors present the first comprehensive evaluation of the immunogenicity of human senescent cells. Their findings demonstrate that, despite exhibiting a unique immunopeptidome, senescent fibroblasts are not recognized by immune cells.
Marie‐Lyn Goyer, Anthony Sonn, Basma Benabdallah, Oanh Le, Joshua Dulong, Joana Oschwald, Isabelle Sirois, Anca Apavaloaei, Leslie Hesnard, Jean V. Guimond, Elie Haddad, Christian Beauséjour   +11 more
wiley   +1 more source

CD155 downregulation synergizes with adriamycin to induce breast cancer cell apoptosis [PDF]

Apoptosis, 2018
CD155 has been implicated in migration, invasion, proliferation and apoptosis of human cancer cells, and DNA damage response caused by chemotherapeutic agents or reactive oxygen species has been shown to attribute to CD155 induction. Adriamycin (Adr) is one of the most common chemotherapeutic drugs used to treat breast cancer.
Gao, Jian, Zheng, Qianqian, Shao, Yue, Wang, Wei, Zhao, Chenghai   +4 more
openaire   +2 more sources

T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Hepatocellular carcinoma (HCC), accounting for over 90% of primary liver cancers, remains a major global challenge for healthcare professionals. While immunotherapy has transformed the landscape of cancer treatment, its success is often limited by immune resistance, particularly through T cell exhaustion which remains a major barrier to ...
Kosar Nouri, Negar Asadollahei, Yasamin Haghir‐Sharif‐Zamini, Homeyra Seydi, Mahsa Salehi, Mehrnaz Mesdaghi, Mustapha Najimi, Massoud Vosough   +7 more
wiley   +1 more source

Development of a novel tumor immunotherapy that targets the soluble poliovirus receptor [PDF]

, 2013
科学研究費助成事業(科学研究費補助金)研究成果報告書：基盤研究(B)2010-2012課題番号 ...
Shibuya Kazuko, 渋谷 和子
core  

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy

Cancer Medicine, Volume 15, Issue 1, January 2026.
We evaluated sequential tumor biopsies during therapy to test the hypotheses that BRAF/MEKi would increase TIL and lead to an expansion of functional intratumoral tumor‐reactive CD8 T‐cells and TIL clonality in the tumor microenvironment. Data from this study provides provocative evidence that, while BRAF+/−MEK inhibitor therapy produces an increase in
Suthee Rapisuwon, Craig L. Slingluff Jr., Jennifer A. Wargo, Ryan J. Sullivan, Benjamin Izar, Jia‐Ren Lin, Ileana S. Mauldin, Walter C. Olson, Christine A. Tran, Gabrielle H. Schwartzman, Geoffrey T. Gibney, Waddah Al‐Refaie, Michael B. Atkins   +12 more
wiley   +1 more source